This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Tumor cells overexpress NK-1 receptors, which are critical for their survival and proliferation. NK-1 receptor antagonists induce apoptosis in tumor cells, inhibit angiogenesis, and reduce tumor cell migration, making them promising targeted anti-cancer agents. Aprepitant, an NK-1 receptor antagonist already clinically approved for other uses, could be repurposed as an effective anti-tumor drug.
Why it matters
Targeting NK-1 receptors offers a new, potentially more specific approach to cancer treatment that may reduce side effects compared to conventional therapies. Repurposing existing drugs like aprepitant could accelerate development of novel cancer treatments.
How the study worked
This is a review article summarizing existing research on the role of substance P, NK-1 receptors, and NK-1 receptor antagonists in cancer biology and treatment potential.
What this study cannot tell us
As a review, the article does not present new experimental data and the clinical effectiveness of NK-1 receptor antagonists as cancer treatments requires further validation through clinical trials.
Read the original research
The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
Journal of biosciences, 40(2), 441-63
Citation
Munoz, Miguel; Covenas, Rafael; Esteban, Francisco; Redondo, Maximino. (2015). The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.. Journal of biosciences, 40(2), 441-63.